PE20151981A1 - Pontenciador de inhibidores del homologo de zeste - Google Patents

Pontenciador de inhibidores del homologo de zeste

Info

Publication number
PE20151981A1
PE20151981A1 PE2015002298A PE2015002298A PE20151981A1 PE 20151981 A1 PE20151981 A1 PE 20151981A1 PE 2015002298 A PE2015002298 A PE 2015002298A PE 2015002298 A PE2015002298 A PE 2015002298A PE 20151981 A1 PE20151981 A1 PE 20151981A1
Authority
PE
Peru
Prior art keywords
zeste
pontencer
approval
inhibitor
dihydropidin
Prior art date
Application number
PE2015002298A
Other languages
English (en)
Inventor
Jr Charles William Blackledge
Joelle Lorraine Burgess
Neil W Johnson
Jiri Kasparec
Steven David Knight
Iii Louis V Lafrance
Xinrong Tian
William Henry Miller
Kenneth Allen Newlander
Stuart Paul Romeril
Mark Schulz
Dai-Shi Su
Juan I Luengo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of PE20151981A1 publication Critical patent/PE20151981A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Esta invencion se refiere a compuestos de acuerdo con la formula (I) que son inhibidores del potenciador de homologo Zeste 2(EZH2), a composiciones farmaceuticas que los contienen, a procedimientos para su preparacion y a su uso en terapia para el tratamiento de canceres. Donde R es H, entre otros; R4 es H, entre otros; X es O, N, etc; Y es O, N, etc; Z es CR5; R1, R2 Y R3 son hidrogeno, alcoxi C1-C4, etc; R5 es alquilo C4-C8, etc; son compuestos preferidos: N-((4,6-dimetil-2-oxo-1,2-dihidropidin-3-il)metil)-4-isopropoxi-3-metiltiofen-2-carboxamida; N-((4,6-dimetil-2-oxo-1,2-dihidropidin-3-il)metil)-4-(etil(tetrahidro-2H-piran-4-il)amino)-3-metiltiofen-2-carboxamida; entre otros
PE2015002298A 2013-04-30 2014-04-25 Pontenciador de inhibidores del homologo de zeste PE20151981A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361817436P 2013-04-30 2013-04-30
US201361842038P 2013-07-02 2013-07-02
US201361907024P 2013-11-21 2013-11-21
US201461936460P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
PE20151981A1 true PE20151981A1 (es) 2016-01-14

Family

ID=50877537

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002298A PE20151981A1 (es) 2013-04-30 2014-04-25 Pontenciador de inhibidores del homologo de zeste

Country Status (20)

Country Link
US (2) US9505745B2 (es)
EP (1) EP2991980B1 (es)
JP (1) JP6373973B2 (es)
KR (1) KR20160003115A (es)
CN (1) CN105308038B (es)
AU (1) AU2014261075B2 (es)
BR (1) BR112015027527A2 (es)
CA (1) CA2910873A1 (es)
CL (1) CL2015003200A1 (es)
DO (1) DOP2015000270A (es)
EA (1) EA030196B1 (es)
ES (1) ES2717680T3 (es)
HK (1) HK1214815A1 (es)
MX (1) MX2015015144A (es)
NZ (1) NZ630205A (es)
PE (1) PE20151981A1 (es)
PH (1) PH12015502414A1 (es)
SG (1) SG11201508203TA (es)
WO (1) WO2014177982A1 (es)
ZA (1) ZA201507398B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862289C (en) * 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN105308038B (zh) * 2013-04-30 2018-05-29 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2的抑制剂
EP3019494B1 (en) 2013-07-10 2017-06-21 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
UA122121C2 (uk) 2014-02-06 2020-09-25 Хептерс Терап'Ютікс Лімітед Біциклічні азотовмісні сполуки як агоністи мускаринового м1 рецептора i/або м4 рецептора
AU2015340614B2 (en) * 2014-10-28 2018-07-19 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AR102767A1 (es) * 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US20190070188A1 (en) * 2015-11-06 2019-03-07 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
DK3378859T3 (da) 2015-11-19 2020-01-20 Jiangsu Hengrui Medicine Co Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
EP3452483B1 (en) * 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
US20170337814A1 (en) * 2016-05-20 2017-11-23 Donald Edward Morgan Safety alerting drivers device and system
MX2019002616A (es) 2016-09-07 2019-09-18 Shanghai Haihe Pharmaceutical Co Ltd Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3089639A1 (en) 2018-01-31 2019-08-08 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022534650A (ja) * 2019-05-31 2022-08-03 海思科医▲薬▼有限公司 Ｂｔｋ阻害薬環誘導体、その調製方法及びその医薬品適用
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
CN110964200A (zh) * 2019-12-19 2020-04-07 新纳奇材料科技江苏有限公司 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法
WO2021129629A1 (zh) * 2019-12-23 2021-07-01 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074642A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Chemical compounds
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US8163749B2 (en) 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
MX2012001413A (es) * 2009-08-07 2012-03-21 Merck Patent Gmbh Compuestos azaheterociclicos novedosos.
EP2566327B1 (en) * 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT3184523T (lt) 2012-04-13 2020-02-10 Epizyme Inc N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CN105308038B (zh) * 2013-04-30 2018-05-29 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2的抑制剂

Also Published As

Publication number Publication date
SG11201508203TA (en) 2015-11-27
HK1214815A1 (zh) 2016-08-05
US20170029412A1 (en) 2017-02-02
CA2910873A1 (en) 2014-11-06
PH12015502414A1 (en) 2016-02-22
US9790212B2 (en) 2017-10-17
ZA201507398B (en) 2017-01-25
MX2015015144A (es) 2016-02-18
US20160102083A1 (en) 2016-04-14
BR112015027527A2 (pt) 2017-07-25
US9505745B2 (en) 2016-11-29
KR20160003115A (ko) 2016-01-08
CN105308038B (zh) 2018-05-29
JP2016517878A (ja) 2016-06-20
AU2014261075B2 (en) 2017-01-19
AU2014261075A1 (en) 2015-11-05
EP2991980B1 (en) 2019-01-02
EA030196B1 (ru) 2018-07-31
CL2015003200A1 (es) 2016-04-22
JP6373973B2 (ja) 2018-08-15
ES2717680T3 (es) 2019-06-24
DOP2015000270A (es) 2016-02-15
EP2991980A1 (en) 2016-03-09
CN105308038A (zh) 2016-02-03
NZ630205A (en) 2017-03-31
EA201592068A1 (ru) 2016-05-31
WO2014177982A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY30748A1 (es) Compuesto0s novedosos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
EA201490357A1 (ru) Индазолы
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
UY35535A (es) ?Derivados de fenil sulfonamidas?.
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CO2018011819A2 (es) Inhibidores del potenciador del homólogo zeste 2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal